menu ☰
menu ˟

Sirion, Acucela sign deal for gene therapy development

12 Jan 2018
Sirion Biotech and Acucela have signed a 2-year development agreement to establish optimized adeno-associated virus vectors for clinical applications in ocular gene therapy, according to a Sirion press release.Through the agreement, which Acucela is ...

Click here to view the full article which appeared in Optometry

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.